NEW YORK – Feb. 13, 2026 – Global law firm Greenberg Traurig, LLP represented Worldwide Clinical Trials (Worldwide), a portfolio company of Kohlberg, in connection with its acquisition of Catalyst Clinical Research (Catalyst), a specialized oncology contract research organization (CRO) known for its expertise in early phase oncology trials and a strong biometrics and Functional Service Provider model.
Catalyst provides highly customizable solutions to the global biopharmaceutical and biotechnology industries through two established, branded solutions: Catalyst Oncology and Catalyst Flex. With more than 1,000 staff and several offices in the United States, Europe, and the Asia-Pacific region, Catalyst provides full-service oncology CRO offerings with Catalyst Oncology and multitherapeutic customer- or Catalyst-managed functional services through Catalyst Flex.
Worldwide is a full-service global CRO that works in partnership with biotechnology and pharmaceutical companies to create customized solutions that advance new medications. Worldwide’s capabilities include bioanalytical laboratory services, Phase I-IV clinical trials, and post-approval and real-world evidence studies — all powered by an accessible team of clinicians, scientists, and researchers who bring firsthand expertise and a collaborative, personalized approach to each clinical program. Worldwide is therapeutically focused on neuroscience, oncology, rare disease, and cardiometabolic and inflammatory disease. Its global footprint spans over 60 countries with more than 3,500 team members.
The multi-office Greenberg Traurig team that represented Worldwide was led by Ejim Peter Achi, co-chair of the firm’s Global Corporate Practice and its Private Equity Practice, andNew York Corporate Shareholders, Sung Jin and Shaun Levor. Other shareholders included Sidney Nunez (Corporate, Houston), Alexander M. Mandel (Corporate, New York), Alexander Sellinger (Corporate, New York), Sarah Moyles (Corporate, London), Samuel Garcia Nelen (Corporate, Amsterdam), Mi Young (Audrey) Lee (Corporate, Seoul), Jeffrey K. Ekeberg (Tax, Chicago), P. Fishel Schreiber (Benefits & Compensation, New York), Nicholas J. Diamond (Health Care & FDA Practice, Houston), Tamara Rizkalla (Healthcare & FDA Practice, Washington, D.C.), Natasha L. Wilson (Labor & Employment, Atlanta), David M. Greenberg (Intellectual Property & Technology, New York), Alison R. Weinberg-Fahey (Real Estate, Silicon Valley ), Sean W. Bezark (Environmental, Chicago), Cyril T. Brennan, (International Trade, Washington, D.C.) and Stephen M. Pepper (Antitrust Litigation & Competition Regulation, New York).
The team also included of counsel: Alex Wang (Corporate, Mexico City), Tzy-Ying (Sandy) Chiu (Intellectual Property & Technology, New York), Megan Eckel (Labor & Employment, Atlanta), and Rebecca Tracy Rotem (Antitrust Litigation & Competition Regulation, Washington, D.C.), and associates: Abdulrasheed Bolaji Ijaodola (Corporate, New York), Junhyung (Jay) Cho (Corporate, New York), Yusuf Olalere (Corporate, London), Grace Lee (Corporate, London), Jazmin Cole (Corporate, London), Marissa Oluwadare (Corporate, London), Jesse Hoek (Corporate, Amsterdam), Minjun Oh (Corporate, Seoul), Byoungjoo Lee (Corporate, Seoul), Holland (Holly) Goldsmith (Benefits & Compensation, New York), Nicole Baptiste (Health Care & FDA Practice, Washington, D.C.), Sukhdeep S. Gill (Intellectual Property & Technology, Philadelphia), Katelyn A. Giel (Real Estate, Phoenix), Madeline Orlando (International Trade, Sacramento), and law clerk/JD Anayo Umeh (Corporate, New York).